TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges

Dylan R. Edwards

doi:10.1002/path.1548

TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges

Dylan R. Edwards

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

The tissue inhibitors of metalloproteinases (TIMPs) control the activities of matrix metalloproteinases (MMPs) and as such, they have been recognized as potential suppressors of angiogenesis and tumour invasion and metastasis. However, TIMP-3 has several unique properties that set it apart from other TIMPs, including its ability to bind to extracellular matrix, inhibit related adamalysin metalloproteinases (ADAMs), and induce apoptosis. New data suggest that high levels of TIMP-3 mRNAs in human breast tumours are associated with success of adjuvant endocrine therapy, but not chemotherapy.

Original language	English
Pages (from-to)	391-394
Number of pages	4
Journal	The Journal of Pathology
Volume	202
Issue number	4
DOIs	https://doi.org/10.1002/path.1548
Publication status	Published - Apr 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/path.1548

Cite this

@article{304e1db594c546cd89fdd35f49f7ea67,

title = "TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges",

abstract = "The tissue inhibitors of metalloproteinases (TIMPs) control the activities of matrix metalloproteinases (MMPs) and as such, they have been recognized as potential suppressors of angiogenesis and tumour invasion and metastasis. However, TIMP-3 has several unique properties that set it apart from other TIMPs, including its ability to bind to extracellular matrix, inhibit related adamalysin metalloproteinases (ADAMs), and induce apoptosis. New data suggest that high levels of TIMP-3 mRNAs in human breast tumours are associated with success of adjuvant endocrine therapy, but not chemotherapy. ",

author = "Edwards, {Dylan R.}",

year = "2004",

month = apr,

doi = "10.1002/path.1548",

language = "English",

volume = "202",

pages = "391--394",

journal = "Journal of Pathology",

issn = "0022-3417",

publisher = "Wiley",

number = "4",

}

TY - JOUR

T1 - TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges

AU - Edwards, Dylan R.

PY - 2004/4

Y1 - 2004/4

N2 - The tissue inhibitors of metalloproteinases (TIMPs) control the activities of matrix metalloproteinases (MMPs) and as such, they have been recognized as potential suppressors of angiogenesis and tumour invasion and metastasis. However, TIMP-3 has several unique properties that set it apart from other TIMPs, including its ability to bind to extracellular matrix, inhibit related adamalysin metalloproteinases (ADAMs), and induce apoptosis. New data suggest that high levels of TIMP-3 mRNAs in human breast tumours are associated with success of adjuvant endocrine therapy, but not chemotherapy.

AB - The tissue inhibitors of metalloproteinases (TIMPs) control the activities of matrix metalloproteinases (MMPs) and as such, they have been recognized as potential suppressors of angiogenesis and tumour invasion and metastasis. However, TIMP-3 has several unique properties that set it apart from other TIMPs, including its ability to bind to extracellular matrix, inhibit related adamalysin metalloproteinases (ADAMs), and induce apoptosis. New data suggest that high levels of TIMP-3 mRNAs in human breast tumours are associated with success of adjuvant endocrine therapy, but not chemotherapy.

U2 - 10.1002/path.1548

DO - 10.1002/path.1548

M3 - Article

VL - 202

SP - 391

EP - 394

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -